Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Accumulated Depreciation & Amortization (2019 - 2025)

Vivos Therapeutics has reported Accumulated Depreciation & Amortization over the past 7 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 5.61% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 5.61% year-over-year, with the annual reading at $2.9 million for FY2025, 5.61% up from the prior year.
  • Accumulated Depreciation & Amortization was $2.9 million for Q4 2025 at Vivos Therapeutics, down from $3.0 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $3.0 million in Q3 2025 and troughed at $874076.0 in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $2.1 million (2023), against an average of $2.0 million.
  • Year-over-year, Accumulated Depreciation & Amortization skyrocketed 55.18% in 2021 and then decreased 1.26% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.2 million in 2021, then skyrocketed by 41.03% to $1.8 million in 2022, then skyrocketed by 32.69% to $2.3 million in 2023, then rose by 19.52% to $2.8 million in 2024, then grew by 5.61% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Accumulated Depreciation & Amortization are $2.9 million (Q4 2025), $3.0 million (Q3 2025), and $2.7 million (Q2 2025).